ABSTRACT Earlier studies showed gross adrenocortical suppression in three workers employed in manufacturing synthetic glucocorticoids. A further nine had either recognisable abnormalities of their responses to tetracosactrin or evidence of chronic skin contact with glucocorticoids. By 1978 the mean morning cortisol concentration of 20 workers employed in active steroid processes was 235 nmol/l + 28-6 (8-5 ,ug/ml + 1 04), which was significantly lower than the value of 428 nmol/l + 37-7 (15.5 ,ug/ml + 1-40) obtained in a control group 
nmol/l + 22-4 (11I1 jug/ml + 08 1), was also significantly lower than this control group (001 > p > 0005). Improvement of protection for workers together with operational and plant changes resulted in a significant rise in the mean morning cortisol values of workers until, in 1979, men employed in all steroid processes had concentrations that did not differ from those of a control group.
Workers employed manufacturing potent glucocorticoids are at risk of absorbing these drugs which may produce a suppression of Adrenocortical suppression in workers employed in manufacturing synthetic glucocorticosteroids had taken place. Subsequently operatives were examined clinically at six-monthly intervals, and blood was taken at 9 am for serum cortisol estimation. Where this was 140 mnol/l (5 ,ug/ml) or less a tetracosactin test was performed.
Continuing evidence of adrenocortical suppression in late 1978 led to more regular screening of serum cortisol concentrations in all the workers employed in the steroid manufacturing process. Subjects were screened at the end of each two-month period in the active steroid processing area and again at the end of a two-month period when they were believed not to have been exposed. The results obtained were compared with the morning plasma cortisol values in a control group of 19 workers who were assessed at the beginning ofemployment with the pharmaceutical company and therefore before possible exposure to glucocorticoid manufacturing processes. In 1979 the criteria for assessing adrenocortical reserve were changed to include men in whom the morning cortisol value was between 140 nmol/l (5 jug/ml) and 280 nmol/l (10 ,ug/ml) on two samples withdrawn within seven days or in whom the cortisol values despite remaining within the normal range showed a fall on three consecutive occasions. The importance of careful environmental monitoring and the close co-operation between management and medical personnel in devising a system of occupational health care for these steroid workers cannot be overestimated.
Results

Work
The value of regular environmental monitoring was established. Closer scrutiny of the physiological activity of certain steroid intermediates showed some activity in two previously believed to be inactive. Increased protection of operators handling these compounds led to improvement in the mean morning serum cortisol value. Determining a safe environmental working level for pharmaceutical compounds is always difficult but becomes increasingly so when the drug is highly active and can be absorbed via the lungs, gastrointestinal tract, and percutaneously. Even with the most up-to-date chemical manufacture complete freedom from exposure cannot be guaranteed. For Newton, Browning, Nicholson, and Mowat certain operations complete protection of the operator will always be necessary together with continued environmental and biochemical monitoring.
Conclusion
The recognition of adrenocortical suppression in workers employed in manufacturing potent glucocorticoids and the steps that have been taken to reduce the hazard have emphasised the value of close co-operation between medical and industrial personnel in achieving a solution. Careful environmental monitoring, regular rotation of operatives awayfrom steroid processes, and an orderly system of biochemical monitoring of operatives have had a considerable effect in reducing adrenocortical suppression in these workers. Unless fully contained processes are in use steroid workers elsewhere must be presumed to be exposed to a similar risk. Lack of symptoms and overt illness should not be accepted as evidence of normal adrenocortical function in those employed in manufacturing glucocorticoids.
